Priorities for 2012
AVAC's Playbook 2012 sets out top strategic goals and priorities in HIV prevention for ourselves—and for the world. Here's what we have to say about PrEP. For more, visit www.avac.org/playbook.What's New
Advocacy in the FDA review of Truvada as PrEPThe FDA public meeting to discuss PrEP is scheduled for May 10. More information on how advocates can be a part of the process is available:
- Read An Advocate's Primer for Public Participation
- Listen to the webinar, Navigating the FDA Review Process
- Follow the proceedings via a live webcast
- For all the latest on this
process, visit www.prepwatch.org
PrEP Data from CROI
- Our Advocates' Summary gives an overview of new data presented at CROI
- View Jared Baeten's CROI presentation, What Can the Twisted Tale of PrEP Results Teach Us?
- Read our latest fact sheet, PrEP using daily oral TDF/FTC or TDF in Women (and Men): What the science tells us in March 2012
New PrEP data show
TDF and TDF/FTC effective in men and
women
- Global teleconference with trial
investigators was held to discuss these
results. Download an mp3
recording here.
- AVAC's statement on these landmark results
- Statements are available from the trial sponsors—the University of Washington and the CDC.
- Other resources:
- Partners Key Facts Partners PrEP FAQ
- Partners PrEP Backgrounder
- CDC Partners PrEP Factsheet
- Q&A
about Partners PrEP and VOICE
- For background on PrEP, see below
Discontinuation of the FEM-PrEP
Trial Disappointing
Continued research to find new ways to end the
HIV epidemic essential
- Global teleconference held to discuss this
development, recording
available here
- Read AVAC's statement on the trial closure
- Read more statements and background information on FEM-PrEP
- To read more on PrEP background, scroll down to the links below
Background on PrEP
Recent research results shows promise for a new HIV prevention strategy called pre-exposure prophylaxis or PrEP. PrEP involves HIV-negative people at risk for HIV using antiretroviral medications (ARVs) to reduce the risk of HIV infection.
The iPrEx trial results were released in November, 2010 and showed that in gay men, transgender women and other men who have sex with men, daily TDF/FTC (tenofovir disoproxyl fumarate plus emtricitabine also known as Truvada) reduced the risk of HIV by 44 percent. Additional studies are ongoing in other populations.
PrEP is not yet recommended for use. Given that iPrEx tested an already licensed drug, there is the potential for immediate, off-label use. In the US, the Centers for Disease Control and Prevention issued interim guidance on PrEP as an HIV prevention strategy for men who have sex with men.
You can get around the PrEP section via the links below (each list includes a few key resources from the section) or navigation to the left. If you are looking for a specific document, try the search box to the right.
Introductory Information
Ongoing Trials and Recent Results
In-depth PrEP Resources
- A Cascade of Hope and Questions
- CDC Interim Guidelines
- Pushing the PrEP Agenda: AVAC’s take and a report from CROI 2011
- PrEP related webinars